Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Table 2

Overview of number of studies and patients available for primary and secondary analyses.

	Progression-free survival	Overall survival
Primary endpoint	trials ( pts)	trials ( pts)
Secondary endpoint: PFS/OS subgroup analyses
Gender (male/female)	= 4 trials ( = 3,017 pts)	= 3 trials ( = 2,651 pts)
Age (cut-off 65 years)	= 4 trials ( = 2,835 pts)	= 3 trials ( = 2,651 pts)
ECOG status (0 versus ≥1)	= 4 trials ( = 2,825 pts)	= 3 trials ( = 2,641 pts)
KRAS status (WT/MUT)	= 4 trials ( = 2,545 pts)	= 3 trials ( = 2,417 pts)
Secondary endpoint: remission/progression analyses
Remission rate	= 5 trials ( = 3,199 pts)
Progression rate	= 4 trials ( = 2,826 pts)
Prevention of progression rate	= 4 trials ( = 2,652 pts)